Control group:When the neutrophil count (ANC) of the subjects < 1.0×109/L, rhG-CSF 5µg/kg/d was given until the ANC=5×109/L. Subjects with FN or dose-limiting neutropenia are allowed to use efbemaleno

Efbemalenograstim alfa for primary prophylaxis of neutropenia in patients during concurrent chemoradiotherapy: a multicenter, prospective, randomized study (Guard-01).

Efficacy and safety of Efbemalenograstim alfa in preventing neutropenia induced by R-CHOP-like regimens in patients with newly diagnosed non-Hodgkin's lymphoma: A randomized controlled multicenter clinical study